Annette Tobia, Ph.D., J.D., Founder, President and CEO
Dr. Tobia is a serial entrepreneur. While a managing partner of QED Technologies, she started and administered virtual companies for venture capital firms. She was acting president of Arcturus Pharmaceutical Co., a dermatology company and a founder of Chemcore, a U of PA Atlas Ventures company, where she established and implemented the patent strategy for the company. ChemCore which was acquired by Caliper because of that strong patent portfolio. Before QED, she was Senior Vice President and General Counsel and founder of British Technology Group, USA (BTG), one of the world's leading technology transfer and licensing companies, as well as managing director of its parent company, BTG plc, a United Kingdom-based company. Prior to that she was Counsel to the President of the Bristol Myers Institute for Medical Research, where she structured strategic alliances with biotech companies and academic institutions.

Frank Kappler, Ph.D. Co-founder and Scientist
Dr. Kappler has a Ph.D. in organic chemistry and has formulated all of the Dynamis products to date. Dr. Kappler also isolated and purified fructoseamine-3-kinase, the enzyme that is the basis for Dynamis’ platform technology. He has designed and synthetized several meglumine analogs that are more potent inhibitors of fructosamine-3-kinase than is meglumine. Dr. Kappler makes frequent presentations at national and international scientific meetings and has authored more than 80 scientific publications and 12 patents.

Alice Marcy, Ph.D., Scientific Operations Officer
Dr. Marcy is a biochemist/molecular biologist and prior to Dynamis worked for 15 years at Merck Research Labs. She has over 20 years of experience with protein expression; assay development, high throughput screening and chemical lead characterization. Dr. Marcy received her Ph.D. from John Hopkins University School of Medicine and did her postdoctoral research at Harvard Medical School.

James Devenny, Ph.D. , Senior Pharmacologist
Dr. Devenny has previously worked for over 18 yrs at Dupont Merck and Bristol-Myers Squibb. He was responsible for the management and coordination of in vitro and in vivo studies in a number of therapeutic areas. His extensive technical expertise in diabetes, diabetic complications, obesity, CNS biology, cardiovascular biology (including angiogenesis and endothelial cell biology studies) and oncology are great assets to Dynamis drug development program. In addition, Dr. Devenny's comprehensive knowledge in compound pharmacokinetics and in vivo biology is critical for Dynamis product development.

Kevin Kimmel, CPA, M.S.T., Director, Corporate Secretary and Treasurer
Mr. Kimmel received his B.S. in accounting from Albright College and his Masters in taxation from Widener University. He is also a certified public accountant. Kevin was a partner in Kimmel, Lorah and Associates CPAs LLP in Valley Forge, PA prior to his own business consulting practice. Mr. Kimmel has extensive experience in financial audits, corporate taxation, and general business planning. Currently he is a director and treasurer of several closely held companies and a member of the American Institute of CPAs and Pennsylvania Institute of CPA’s.

Erika Geimonen, Ph.D., M.S., VP Business Development
Dr. Geimonen has over 20 years of experience in business development and research. Prior to Dynamis, Erika was VP Business Development for XBiotech, a biotech company targeting inflammation by using novel native human antibodies. Prior to that she held business development positions at Schering-Plough and Luitpold Pharmaceuticals, a subsidiary of Daiichi-Sankyo group. She is also a co-chair of Philadelphia chapter of Licensing Executive Society.

Scientific Board of Advisors

Simeon Taylor, M.D., Ph.D.
Currently Dr. Taylor is consultant to University of Maryland School of Medicine, National Institute of Diabetes, Digestive and Kidney Diseases. Previously Dr. Taylor was as VP of Research & Scientific Affairs and VP of Drug Discovery Biology at Bristol-Myers Squibb, and Chief, Diabetes Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He received his MD and PhD degrees from Harvard University.

All Rights Reserved

About Dynamis Therapeutics, Inc. Drug Development News Personnel Contact Us